A systematic review on hepatocellular carcinoma: diagnosis and therapies for patients
Hepatocellular carcinoma is the most common primary malignancy of the liver in adults. Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, prevalence and mortality rates. HCC is the fifth most common cancer and the third cause of cancer-related mortality worldwide. Its incidence is clearly arising comprised by the prevalence of major risk factors mainly hepatitis B and hepatitis C. The population at risk is composed of chronic liver patients at the stage of extensive fibrosis or cirrhosis. The monitoring programs of this population have allowed early detection of disease management to promote a radical therapy. Understanding the carcinogenic process and the mastery of the staging systems remain essential keys in diagnosis and treatment of HCC. Recent advances in diagnosis and new treatments have made important impacts on the disease by increasing survival rates and improving quality of life for HCC patients.
Keywords: Hepatocellular carcinoma (HCC), hepatitis B and hepatitis C, radical therapy, new treatments.
2. Dienstag JL, Isselbacher KJ, Toxic and drug‐induced hepatitis, 15th edn. Chapter 296, In: Harrison's Principles of Internal Medicine. Braunwald E, et al, The McGraw‐Hill Companies, In, 2001; 2:737‐1742.
3. International Agency for Research on Cancer, 2011. http://www-dep.iarc.fr
4. Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA; Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo). 2010; 65:1295-90.
5. Kumar V, Abbas AK, Aster JC, editors. Robbins & Contran. Pathologic Basis of Diseases. 9th ed. Philadelphia: Elsevier; 2014.
6. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 32 patients. Hepatogastroenterology 1998; 45(Suppl 3):1214-20.
7. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150:835-53.
8. Patel, J. Anticancer & cytotoxic potential of aqueous extract of Triticum aestivum on hela cell line. Journal of Drug Delivery and Therapeutics, 2016; 6(3):84-89. https://doi.org/10.22270/jddt.v6i3.1211
9. Anand R, Aflatoxins, in: IARC monograph on the evaluation of carcinogenic risks to humans, vol. 82, in: Some Traditional Herbal Medicines Some Mycotoxins, Naphthalene and Styrene, McGraw- Hill, New York, 2002, pp. 171–300.
10. Corrao G, Bagnardi V, Zambon A, C. La Vecchia, A meta-analysis of alcohol consumption and the risk of 15 diseases, Prev. Med. 2004; 38:613–619.
11. Shu-Chun Chuang a, Carlo La Vecchia b,c, Paolo Boffetta a,* Cancer Letters 286 (2009) 9–14
12. Trevisani F, D'lntino PE, Grazi GL, Caraceni P, Gasbarrini A, Colantom A, Stefamni GF, Mazzlotti A, Gozzetti G, Gasbarrini G, Bernard~ M. Chmcal and pathologic features of hepatocellular carcinoma in young and older Itahan patients. Cancer 1996; 77:2223-2232.
13. Colher J, Sherman M. Screening for hepatocellular carcinoma.Hepatology 1998; 27:273-278.
14. Sato Y, Nakata K, Kato Y, Shima M, Ishd N, Koji T, Taketa K, Endo Y, Nagataki S. Early recogmtion of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993; 328:1802-1806
15. Krinsky GA. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219:445-454.
16. Mazzaferro V, Bhoori S, Sposito C, et al., “Milan Cri-teria in Liver Transplantation for HCC: An Evidence- Based Analysis on 15 Years of Experience,” Liver Trans- plantation, 2011; 17(2):S44-S57.
17. Handa SS, Sharma A and Chakraborti KK. Natural products and plants as liver protecting drugs. Fitoterapia. 1986;57(5):307-352.
18. Gonz´alez-Uriarte J, Valdivieso A, Gastaca M et al., “Liver transplantation for hepatocellular carcinoma in cirrhotic patients,” Transplantation Proceedings, vol. 2003; 35(5):1827–1829.
19. Tanwar S, Khan SA, V. P. B. Grover, C. Gwilt, B. Smith, and A. Brown, “Liver transplantation for hepatocellular carcinoma,” World Journal of Gastroenterology, 2009; 15(44):5511–5516,.
20. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228:235–240.
21. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127:S159–166.
22. Bruix J, Llovet JM, “Locoregional treatments for hepatocellular carcinoma,” Best Practice and Research Clinical Gastroenterology, vol. 14, no. 3, pp. 611–622, 1999.
23. Villanueva A, Newell P, Hoshida Y, “Inherited hepatocellular carcinoma,” Best Practice and Research Clinical Gastroenterology, vol. 2010; 24(5):725–734.
24. Sangro B, Bilbao JI, M. I˜narrairaegui, M. Rodriguez,P. Garrastachu, and A. Martinez-Cuesta, “Treatment of hepatocellular carcinoma by radioembolization using y microspheres,” Digestive Diseases, vol. 27, no. 2, pp. 164–169,2009.
25. Sangro B, Carpanese L, Cianni R et al., “Survival after Yttrium-90 resin microsphere radioembolization of hepatocellularcarcinoma across barcelona clinic liver cancer stages: a European evaluation,” Hepatology, vol. 54, no. 3, pp. 868– 878, 2011.
26. Witjes CDM, Verhoef C, Verheul HMW, and Eskens F. A. L.M., “Systemic treatment in hepatocellular carcinoma;‘a small step forman...’,” Netherlands Journal of Medicine, 2009; 67(3):86–90.
27. C. M. Lo, S. T. Fan, C. L. Liu, S. C. Chan, and J. Wong, “The role and limitation of living donor liver transplantation for hepatocellular carcinoma,” Liver Transplantation, 2004; 10(3):440–447.
28. Raoul JL, Guyader D, Bretagne JF, et al., “Pros- pective Randomized Trial of Chemoembolization versus Intraarterial Injection of 131I-Labeled-Iodized Oil in the Treatment of Hepatocellular Carcinoma,” Hepatology, 1997; 26(5):1156-1161
29. Kulik LM, Carr BI, Mulcahy MF, et al., “Safety and Efficacy of 90Y Radiotherapy for Hepatocellular Carci- noma with and without Portal Vein Thrombosis,” Hepa- tology, 2008; 47(1):71-81.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).